Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response

Melanoma Res. 2023 Dec 1;33(6):553-555. doi: 10.1097/CMR.0000000000000918. Epub 2023 Oct 25.

Authors

Elena Carmona-Rocha^{1

2}, Ivana Sullivan^{2

3}, Oriol Yélamos^{1

2}

Affiliations

¹ Dermatology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona.
² Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU).
³ Oncoloy Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

PMID: 37890183
DOI: 10.1097/CMR.0000000000000918

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Humans
Melanoma* / drug therapy
Mutation
Oximes / adverse effects
Proto-Oncogene Proteins B-raf / genetics
Proto-Oncogene Proteins B-raf / therapeutic use
Pyridones / therapeutic use
Pyrimidinones / therapeutic use
Skin Neoplasms* / drug therapy
Vitiligo* / chemically induced

Substances

dabrafenib
trametinib
Oximes
Pyridones
Pyrimidinones
Proto-Oncogene Proteins B-raf